Расширенный поиск

Беклоджет: новые технологии доставки ингаляционных глюкокортикостероидов

Полный текст:

Об авторе

С. Н. Авдеев
НИИ пульмонологии Минздрава РФ


Список литературы

1. Авдеев С.Н. Устройства доставки ингаляционных препаратов, используемые при терапии заболеваний дыхательных путей. Рус. мед. журн. 2002; 10 (5): 255-261.

2. Сенкевич Н Ю ., Белевский. А.С., Мещерякова Н.Н. Пути повышения кооперативности больных бронхиальной астмой. Астма.ги 2001; 0: 25-28.

3. Agertoft L., Pedersen S. Influence of spacer device on drug delivery to young children with asthma. Arch. Dis. Child. 1994;71:217-220.

4. Balbi B., Majori М ., Bertacco S. et al. Inhaled corticoids in stable COPD patients. Do they have effects on cells and molecular mediators of airway inflammation? Chest 2000; 117: 1633-1637.

5. Barnes P.J., Pedersen S., Busse W. Efficacy and safety of inhaled corticosteroids. Am. J. Respir. Crit. Care Med. 1998; 157: S1-S53.

6. Bisgaard H., Anhoj J., Klug B., Berg E. A non-electrostatic spacer for aerosol delivery. Arch Dis Child 1995; 73: 226-230.

7. Bousquet J. Introduction ModuliteT: simplifying the changeover. Respir. Med. 2002; 96 (suppl.D): S1-S2.

8. Bousquet J., Cantini L. Clinical studies in asthmatics with a new non-extrafine HFA formulation of beclomethasone dipropionate (BD P ModuliteT). Ibid. S17-S27.

9. Brambilla G., Ganderton D., Garzia R. et al. Modulation of aerosol clouds produced by pressuiised inhalation aerosols. Int. J. Pharm. 1999; 186: 53-61.

10. Burge P.S., Calverley P.M., Jones P.W. et al. On behalf of the ISOLDE study investigators. Randomised, double blind, placebo controled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. J. 2000; 320: 1297-1303.

11. Cochrane M .G., Bala M .V., Downs K.E. et al. Inhaled corticosteroids for asthma therapy. Patient compliance, devices, and inhalation technique. Chest 2000; 117: 542-550.

12. Confalonieri М ., Mainardi E., Della Porta R. et al. Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax 1998; 53: 583-585.

13. Donnell D., Harrison L.I., Ward S. et al. Acute safety of the CFC-free propellant HFA-134a from a pressurized metered dose inhaler. Eur. J. Clin. Pharmacol. 1995; 48: 473-477.

14. Ganderton D., Lewis D., Meakin B. et al. Pharmaceutical aerosol composition. WO Pat. Appl. 1998; № 98/56349.

15. Ganderton D. Targeted delivery of inhaled drugs: current challenges and future goal. J. Aerosol Med. 1999; 12 (suppl.l): S3-S8.

16. Ganderton D., Lewis D., Davies R. et al. ModuliteT: a means of designing the aerosols generated by pressurized metered dose inhalers. Respir. Med. 2002; 96 (suppl.D): S3-S8.

17. Girbino G., Lauriello G., Ando F., Cantini L. Beclomethasone dipropionate given to adult asthmatics through a new spacer device: effects of high-dose administration. Adv. Ther. 1996; 13: 220-229.

18. Global strategy for asthma management and prevention N H LBI/W H O Workshop Report: NIH Publication № 02-3659. The 2002 report is available on

19. Haahtela Т., Jarvinen М ., Kava T. et al. Comparison of a beta2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N. Engl. J. Med. 1991; 325: 388-392.

20. Harrison L.I., Donnel D., Simmons J.L. et al. Twenty-eight-day double-blind safety study of an HFA-134a inhalation aerosol system in healthy subjects. J. Pharm. Pharmacol. 1996; 48: 596-600.

21. Hayman G. Why the environment matters. Br. J. Clin. Pract. 1995; 49 (suppl.): 2-6.

22. June D. Achieving to change: challenges and successes in the formulation of CFC-free MDIs. Eur. Respir. Rev. 1997; 7 (41): 32-34.

23. Leach C.L. Safety asessment of the HFA propellant and the new inhaler. Ibid. 35-36.

24. Leach C.L., Davidson P.J., Boudreau R.J. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur. Respir. J. 1998; 12: 1346-1353.

25. Lefrancois G., Rocca-Serra J.P, Umile A. A new non-ultra-fine BDP HFA-134a formulation: clinical equivalence of efficacy and safety vs CFC formulation. Am. J. Respir. Crit. Care Med. 2001; 163 (suppl.): A441.

26. Lipworth B.J. Targets for inhaled treatment. Respir. Med. 2000; 94 (suppl.D): S13-S16.

27. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N. Engl. J. Med. 2000; 343: 1902-1909.

28. Matthys H., Umile A. Holding chambers for pMDI use. Drugs Exp. Clin. Res. 1997; 23 (5/6): 183-189.

29. Matthys H. CFCs and their effect on the ozone layer: the Montreal Protocol and consequences for physicians. Eur. Respir. Rev. 1997; 7 (41), 29-31.

30. Molina M.J., Rowland F.S. Stratospheric sink for chlorofluoromethanes: chlorine atom catalyzed destruction of ozone. Nature 1974; 249: 810-814.

31. Nelson H.S., Busse W .W ., de Boisblanc B.P. et al. Fluticasone propionate powder: oral corticosteroid-sparing effect and improved lung function and quality of life in patients with severe chronic asthma. J. Allergy. Clin. Immunol. 1999; 103: 267-275.

32. Newm an S.P., Weisz A .W .B ., Talaee N. et al. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax 1991; 46: 712-716.

33. Paggiaro P.L., Dahle R., Bakran I. et al. Multicentre randomised placebo controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 1998; 351: 773-780.

34. Pauwels R.A., Lofdahl C.G., Laitinen L.A. et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N. Engl. J. Med. 1999; 340: 1948-1953.

35. Rocca-Serra J.P., Vicaut E., Lefrancois G., Umile A. Efficacy and tolerability of a new non-extrafine formulation of beclomethasone HFA-134a in patients with asthma. Comparison with beclomethasone CFC. Clin. Drug Invest. 2002; 22: 653-665.

36. Secretariat of the Montreal Protocol. Montreal protocol on substances that deplete ozone layer- 1987 [online]. Available from URT:

37. Suissa S., Ernst P., Benayoun S. et al. Low-dose inhaled corticosteroids and the prevention of death from asthma N. Engl. J. Med. 2000; 343: 332-336.

38. Tansey T. The technical transition to CFC-free inhalers. Br. J. Clin. Pract. 1997; suppl.; 89: 22-27.

39. Tashkin D.P. New devices for asthma. J. Allergy Clin. Immunol. 1998; 101: S409-S416.

40. United Nations Environment Programme Technology and Economic Assessment Panel of the Montreal Protocol on substances that deplete the ozone layer. Part III Update of the 1994 T.O.C. Aerosols Report and the MDI Transition Strategy, TEAP 1996.

41. Vecchiet L., Pieralisi G., Ambrosi L. et al. Inhaled beclomethasone dipropionate administered through a new spacer device: a controlled clinical study. Adv. Ther. 1996; 13: 335-346.

42. Vestbo J., Sorensen Т., Lange P. et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819-1823.

43. Woodcock A., Acerbi D., Poll G. ModuliteT technology: pharmacodynamic and pharmacokinetic implications. Respir. Med. 2002; 96 (suppl.D): S9-S15.


Для цитирования:

Авдеев С.Н. Беклоджет: новые технологии доставки ингаляционных глюкокортикостероидов. Пульмонология. 2003;(3):115-119.

For citation:

Avdeev S.N. Beclojet: new techniques of delivery of inhaled glucocorticosteroids. PULMONOLOGIYA. 2003;(3):115-119. (In Russ.)

Просмотров: 23

ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)